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Background. Fixed-dose combination scored dispersible stavudine, lamivudine, and nevirapine minitablets
(Triomune Baby and Junior; Cipla Ltd) are simpler and cheaper than liquid formulations and have correct dose
ratios for human immunodeficiency virus–infected children. However, they cannot be used for dose escalation
(DE) of nevirapine.
Methods. Children were randomized to initiate antiretroviral therapy with full-dose (FD) nevirapine (Triomune
Baby or Junior in the morning and evening) versus DE (half-dose nevirapine for 14 days [Triomune in the morning
and stavudine-lamivudine {Lamivir-S} in the evening], then FD), in accordance with World Health Organization
weight-band dosing tables. The primary end point was nevirapine-related clinical or laboratory grade 3 or 4 adverse
events (AEs).
Results. In total, 211 children (median [interquartile range {IQR}] age, 5 [2–9] years; median [IQR] CD4 cell
percentage, 13% [8%–18%]) were enrolled and followed up for a median (IQR) of 92 (68–116) weeks. There
were 31 grade 3 or 4 AEs that were definitely/probably or uncertainly related to nevirapine in the FD group (18.0
per 100 child-years), compared with 29 in the DE group (16.5 per 100 child-years) (incidence rate ratio, 1.09;
95% confidence interval, 0.63–1.87; ). All were asymptomatic; 11 versus 3 were single grade 3 or 4 elevationsPp .74
in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels, all of which resolved without a
change in nevirapine dose or interruption. Thirteen (12%) FD versus 2 (2%) DE children had grade 1 (2 in FD)
or grade 2 (11 in FD and 2 in DE) rashes. Three (2 in FD and 1 in DE) substituted efavirenz, 3 (FD) continued
FD nevirapine, and 9 (8 in FD and 1 in DE) temporarily interrupted nevirapine, followed by successful DE.
Predictors of nevirapine rash were older age ( ) and higher CD4 cell count for age ( ). Twenty-Pp .003 Pp .03
two children died (12 in FD and 10 in DE), 1 FD and 5 DE children at !4 weeks; none were considered to be
drug related by independent review.
Conclusions. Rash was more frequent with FD nevirapine, but 88% had no clinical toxicity; elevated AST or
ALT levels were transient and resolved spontaneously, suggesting that routine laboratory monitoring has limited
value. Dual pediatric stavudine-lamivudine minitablets are preferred for safe and simple DE; if unavailable, initiating
FD Triomune requires timely review for rash, which could be managed by temporary reduction to half-dose
Triomune or efavirenz substitution.
Trial registration. Current Controlled Trials identifier: ISRCTN31084535.
In December 2008, most of the ∼2 million children in-
fected with human immunodeficiency virus (HIV) were
Received 17 March 2010; accepted 29 June 2010; electronically published 24
September 2010.
Reprints or correspondence: Prof Diana M. Gibb, MRC Clinical Trials Unit, 222
Euston Rd, London, NW1 2DA, United Kingdom (dmg@ctu.mrc.ac.uk).
Clinical Infectious Diseases 2010; 51(9):1081–1089
 2010 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2010/5109-0014$15.00
DOI: 10.1086/656628
living in sub-Saharan Africa; only 35% of the 640,000
who needed antiretroviral therapy (ART) there were re-
ceiving it [1]. One major challenge to scaling up pediatric
ART has been the lack of appropriate antiretroviral drug
formulations [2, 3]. Syrups are up to 6 times more ex-
pensive than solid formulations, are difficult to transport
and store, and have short shelf lives, making them in-
appropriate for most resource-limited settings [2]. Syr-
ups also cannot easily be coformulated and, with different
drugs having different volumes, are complex to measure
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and administer. In contrast, fixed-dose combination (FDC) solid
scored tablets, which can be dispersed or crushed and dosed
according to weight-band tables, are easier for health workers to
prescribe and carers to administer.
Until recently, adult FDC tablets (stavudine, lamivudine, and
nevirapine) cut into parts were commonly used to treat HIV-
infected children in resource-limited settings [4, 5]. However,
lack of scoring, lack of dosing flexibility (as the child grows),
and inappropriate ratios of the individual drugs for younger
children because of varying drug metabolism with age results
in inaccurate dosing—in particular, nevirapine underdosing—
with concomitant risks of resistance emergence [5]. Cipla Ltd
developed 2 triple-drug FDC tablets with the correct drug ra-
tios for children, Triomune Baby and Triomune Junior (6 and
12 mg of stavudine, respectively; 30 and 60 mg of lamivudine,
respectively; and 50 and 100 mg of nevirapine, respectively).
These are small scored dispersible tablets providing appropriate
pharmacokinetic levels for children when given in accordance
with World Health Organization (WHO)–recommended
weight-band dosing tables [6]. However, to escalate the nevir-
apine dose as recommended, common practice in Zambia has
been to initiate ART using 3 syrups, changing to triple FDC
tablets 2 weeks later.
Nevirapine toxicity has been reported to be relatively un-
common among children, both in the United States [7, 8] and
Africa, where a Ugandan study found few problems using full-
dose (FD) adult Triomune tablets in children from ART ini-
tiation [9]. However, there are few prospective pediatric data
on nevirapine toxicity, and no randomized trials have evaluated
the safety of starting with FD nevirapine immediately in either
adults or children.
METHODS
CHAPAS-1 (Children with HIV in Africa—Pharmacokinet-
ics and Adherence of Simple Antiretroviral Regimens) was an
open, randomized trial conducted at the University Teaching
Hospital, Lusaka, Zambia (ISRCTN31084535). Children aged
3 months to 14 years with confirmed HIV infection and no
history of ART (including for prevention of mother-to-child
transmission) who fulfilled WHO 2006 guidelines for ART ini-
tiation [10] were enrolled. Children were randomized to initiate
ART with FD triple-drug FDC Triomune Baby or Junior twice
daily for 2 weeks (the FD group) or to Triomune Baby or Junior
once daily for the first 2 weeks, together with once-daily La-
mivir-S (dual-drug Baby [6 mg of stavudine and 30 mg of
lamivudine] or Junior [twice the dose for Baby] FDC; the dose
escalation [DE] group). After 2 weeks, DE children discontin-
ued Lamivir-S and continued with Triomune Baby or Junior
twice daily. Lamivir-S Baby and Junior were produced by Cipla
for CHAPAS-1.
Randomization was in a 1:1 ratio, stratified by age (3 months
to 6 years and 7–14 years). A computer-generated sequential
randomization list, constructed using variable block size, was
prepared in advance by the trial statistician and incorporated
securely into the trial database. The list was fully concealed
until allocation, after eligibility had been established and a ran-
domization request made to data management staff.
All children (regardless of randomized group) were seen by
a nurse 2 and 4 weeks after randomization (ART initiation)
and then every 4 weeks until the last child reached 48 weeks
(October 2008). At each visit, children were weighed and mea-
sured, any adverse events (AEs) or new WHO events were
recorded, and additional ART was prescribed. Children were
routinely seen by a doctor at weeks 2, 4, 8, and 12 and then
every 12 weeks. Doctors conducted a clinical examination, and
blood samples were obtained for hematology, biochemistry, and
lymphocyte subsets and plasma storage.
The primary outcome was grade 3 or 4 AEs definitely/prob-
ably or uncertainly related to nevirapine. Secondary outcomes
were grade 2–4 AEs definitely/probably related to nevirapine;
adherence, determined on the basis of questionnaires and pill
counts; mortality; disease progression, determined on the basis
of new WHO stage 3 or 4 events; viral load, measured retro-
spectively in stored postbaseline samples by means of the Roche
Amplicor 1.5 test (lower limit of detection, 250 copies/mL [be-
cause of small volumes requiring dilution]); growth and changes
in CD4 cell count and percentage from baseline; and the phar-
macokinetic parameters of nevirapine, lamivudine, and stavudine
[6]. All WHO 3 or 4 events, deaths, and grade 3 or 4 AEs were
reviewed without knowledge of randomized group by the End
Point Review Committee, which comprised the United Kingdom
principal investigator (D.M.G.) and a clinician from the Uni-
versity Teaching Hospital (C. Kankasa) who was not involved in
CHAPAS-1 clinical care.
The sample size of 200 children provided 80% power to
detect a 15% absolute increase in nevirapine-related grade 3 or
4 AEs, from 10% in the DE group to 25% in the FD group
(1-sided ). Fifteen percent was the minimum increaseap .05
in toxicity judged to be clinically relevant to detect: we could
not find any data on expected FD rates in adults or children.
When enrollment was nearly complete, few children had been
entered into the lowest 3–6-kg dosing band. To enable phar-
macokinetic analysis in this subgroup, the sample size was in-
creased to 210 and recruitment was limited to very young chil-
dren to be followed only to October 2008 [11]. An independent
data-monitoring committee reviewed the study twice, in Feb-
ruary 2007 and June 2008, and on both occasions recom-
mending continuation.
All analyses were done on an intention-to-treat basis. Com-
parison of event rates between randomized groups used per-
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Figure 1. CONSORT (Consolidated Standards of Reporting Trials) flow diagram. The asterisk (*) indicates that the child was mistakenly considered
to not meet World Health Organization criteria for antiretroviral therapy (ART) and was not prescribed drugs or followed up.
son-time analysis, comparing rate ratios by exact 2-sided sig-
nificance tests. Mortality analyses used time-to-event surviv-
al methods, comparing hazard ratios (HRs) by log-rank tests.
Predictors of nevirapine reactions were investigated by mul-
tivariable logistic regression, using backward elimination with
Akaike’s information criterion. Global comparisons between
randomized groups in changes in adherence, CD4 cell count
and percentage, viral load, and anthropometric parameters to
96 weeks were analyzed using generalized estimating equations.
Weight-for-age and height-for-age z scores were determined
using the British 1990 reference [12], because it covers the full
age range of CHAPAS-1 children. Stata software, version 10
(StataCorp), was used in all analyses.
RESULTS
Between February 2006 and October 2007, 204 children were
randomized. An additional 8 children weighing 3–6 kg and !2
years old were randomized to June 2008. One child was ran-
domized in error (mistakenly considered to not meet WHO
criteria for ART and not prescribed drugs or followed up) and
was excluded from analysis. Thus, the intention-to-treat anal-
yses included 211 children, 105 in the FD group and 106 in the
DE group (Figure 1).
Baseline characteristics were reasonably balanced between
randomized groups (Table 1). The median age at ART initiation
was 5 years (35% were !3 years old). Severe wasting and/or
stunting were common, with 150% children having weight-
for-age and height-for-age z scores below 3 and none having
scores above zero. Ninety-nine percent had WHO stage 3 or 4
HIV disease, and 58% had a CD4 cell percentage !15%.
The median duration of follow-up to October 2008 was 92
weeks (interquartile range [IQR], 68–116 weeks). Seventeen
children (8%) were not known to have died and were not seen
during October 2008 (trial closure); their median duration of
follow-up was 25 weeks (IQR, 12–44 weeks), with 2 of 17 not
seen after randomization. Changing residence was the most
common reason for losses to follow-up.
All children initiated ART within 1 day of randomization.
One hundred DE children (94%) completed DE after a median
of 14 days (IQR, 14–15 days; range, 12–35 days); the remaining
6 either died (3), were lost to follow-up (1), or substituted
efavirenz for nevirapine within 14 days (1 rash and 1 tuber-
culosis cotreatment). In total, nevirapine was interrupted 32
times in 28 children, 19 (18%) in the FD group and 9 (8%)
in the DE group (exact ). Thirteen substitutions (8 inPp .04
FD and 5 in DE) with efavirenz or abacavir were due to tu-
berculosis cotreatment, 13 changes (11 in FD and 2 in DE)
were for AEs (temporary nevirapine interruption [11] or efa-
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Table 1. Baseline Characteristics and Follow-up
Characteristic
FD
(n p 105)
DE
(n p 106)
All
(n p 211)
Male sex 56 (53) 55 (52) 111 (53)
Age
Median years (IQR) 5.2 (1.6–9.5) 5.7 (2.2–8.7) 5.6 (2.0–9.0)
0–2 years 40 (38) 34 (32) 74 (35)
3–6 years 26 (25) 33 (31) 59 (28)
7–10 years 23 (22) 30 (28) 53 (25)
11–14 years 16 (15) 9 (8) 25 (12)
Median z score (IQR)
Weight for agea 3.3 (4.3 to 2.2) 3.0 (4.2 to 2.1) 3.2 (4.3 to 2.1)
Height for agea 3.1 (4.2 to 2.4) 3.1 (4.1 to 2.0) 3.1 (4.1 to 2.2)
WHO HIV stage
1 or 2 2 (2) 0 (0) 2 (1)
3 68 (65) 68 (64) 136 (64)
4 35 (33) 38 (36) 73 (35)
CD4 cell percentage
Median percentage (IQR) 13 (9–18) 12 (8–18) 13 (8–18)
0%–4% 16 (15) 9 (9) 25 (12)
5%–14% 43 (41) 54 (51) 97 (46)
15%–24% 37 (35) 34 (32) 71 (34)
25% 9 (9) 8 (8) 17 (8)
CD4 cell count, median cells/mL (IQR)
All patients 452 (231–824) 437 (245–797) 441 (235–819)
Age 0–2 years 753 882 824
Age 3–6 years 557 422 528
Age 7–10 years 215 306 274
Age 11–14 years 241 246 246
Follow-up
Median weeks (IQR) 90 (68–113) 96 (68–116) 92 (68–116)
Lost to follow-up 9 (9) 8 (8) 17 (8)
NOTE. Data are no. (%) of patients, unless otherwise indicated. DE, dose escalation; FD, full dose; HIV, human immu-
nodeficiency virus; IQR, interquartile range; WHO, World Health Organization.
a British 1990 growth reference [12].
virenz substitution [2]), and 6 were for nonmedical reasons (4
in FD and 2 in DE). No child switched to second-line treatment.
Adherence was good: carers reported that their child had not
missed medication at 92% of nurse visits (91% in DE and 93%
in FD; ).Pp .28
AEs. Sixty (31 in FD and 29 in DE) grade 3 or 4 AEs
occurring in 49 children (25 in FD and 24 in DE) were judged
to be definitely/probably related to nevirapine ( ) or tonp 8
have an uncertain status with respect to their relationship with
nevirapine ( ) by the End Point Review Committee (FD:np 52
DE incidence rate ratio [IRR], 1.09; 95% confidence interval
[CI], 0.63–1.87; ) (Table 2 and Figure 2A). All werePp .74
asymptomatic laboratory AEs, and all children continued ne-
virapine therapy without interruption or dose change. Most
frequent events were elevated aspartate aminotransferase (AST)
or alanine aminotransferase (ALT) levels (11 in FD and 3 in
DE, all single values; 8 [7 in FD and 1 in DE] were judged to
be definitely/probably related to nevirapine on the basis of tim-
ing) and elevated bilirubin levels ( ).np 34
Forty (26 in FD and 14 in DE) grade 2–4 AEs occurring in
34 children (22 in FD and 12 in DE) were judged to be defi-
nitely/probably related to nevirapine (FD:DE IRR, 1.89; 95%
CI, 0.95–3.92; ) (Table 2 and Figure 2B). These includedPp .05
14 grade 2 rashes (12 in FD [including 1 repeat rash] and 2
in DE), 25 asymptomatic elevated AST or ALT levels (13 in FD
and 12 in DE), and 1 elevated alkaline phosphatase level (FD).
No child developed a grade 3 or 4 rash, but 13 (12%) FD
versus 2 (2%) DE children had grade 2 (11 in FD and 2 in
DE) or grade 1 (2 in FD) rashes (exact ), all judgedPp .003
to be definitely/probably related to nevirapine. Only 1 child
(FD) had a second grade 2 rash after rechallenge with half-
dose nevirapine. Rashes started a median of 17 days (range, 8–
25 days) after ART initiation, with a median duration of 9 days
(range, 2–24 days). In 3 FD versus 0 DE children, grade 1
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Table 2. Adverse Events (AEs)
Category, parameter
FD
(n p 105)
DE
(n p 106)
FD:DE
rate ratio (95% CI) P
Grade 3 or 4 AEs with a definite/probable or un-
certain relationship with nevirapine (primary
end point)
Children with at least 1 event, no. (%) 25 (24) 24 (23)
Total events 31 29
Child-years at risk 173 176
Rate, events per 100 child-years 18.0 16.5 1.09 (0.63–1.87) .7
Type of event
Biochemical 30 29
Elevated liver enzyme level (AST or ALT) 11 3
Elevated alkaline phosphatase level 6 4
Elevated bilirubin level 13 21
Elevated creatinine level 0 1
Hematological 1 0
Thrombocytopenia 1 0
Grade 2–4 AEs with a definite/probable relation-
ship with nevirapinea (secondary end point)
Children with at least 1 event, no. (%) 22 (21) 12 (11)
Total events 26 14
Child-years at risk 173 176
Rate, events per 100 child-years 14.5 8.0 1.89 (0.95–3.82) .05
Type of event
Biochemical 14 12
Elevation in liver enzyme level (AST or ALT) 13 12
Elevation in alkaline phosphatase level 1 0
Clinical 12b 2
Rash 12b 2
NOTE. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; DE, dose escalation;
FD, full dose.
a Not including events with an uncertain relationship.
b Including 2 rashes in 1 child rechallenged with half-dose nevirapine and substituting efavirenz; in total, 11 FD children
had grade 2 rashes (and 2 FD children had grade 1 rashes).
( ) or 2 ( ) rash was associated with transient gradenp 2 np 1
3 elevated AST or ALT levels. Of the 15 children who developed
rash, 3 (FD) continued FD nevirapine; 9 (8 in FD and 1 in
DE) temporarily stopped nevirapine (by substituting Lamivir-
S for a median of 8 days [range, 6–8 days]) and then successfully
escalated the dose of nevirapine; 1 (FD), in whom rash returned
after interruption and DE, substituted efavirenz for nevirapine;
and 2 (1 in FD and 1 in DE) substituted efavirenz without
retrying half-dose Triomune. All but 2 children (both FD) were
managed as outpatients; 2 were admitted for observation (1
early during the trial and 1 during successful continuation of
FD nevirapine). In multivariable regression models, nevirapine
reactions (either rash alone [15/211; 7%] or rash or definitely/
probably nevirapine-related grade 3 or 4 elevated AST or ALT
level [21/211; 10%]) were significantly more common both in
older children and in those with higher CD4 cell counts for
age (Table 3). The risk was also nonsignificantly higher for girls.
HIV-related events. Twenty-two (10%) children died (6.9
and 5.7 deaths per 100 child-years in the FD and DE groups,
respectively; FD:DE HR, 1.19; 95% CI, 0.51–2.75; ). NoPp .7
deaths were judged to be drug related, and most occurred soon
after randomization: 6 (1 in FD and 5 in DE) during the first
4 weeks and 6 more (4 in FD and 2 in DE) during weeks 4–
12. The cause of death was most frequently diarrhoea ( )np 7
or serious lung disease ( ); most children who died hadnp 3
advanced HIV infection and very low weight-for-age z scores
(mean, 4.5) at ART initiation.
Five new or recurrent WHO stage 4 events and 19 stage 3
events occurred in 21 children. WHO stage 3 events were mostly
pulmonary tuberculosis ( ) or oral candidiasis ( );np 10 np 8
3 stage 4 events were extrapulmonary tuberculosis. Overall, 40
children had a WHO stage 3 or 4 event and/or died (19%)—
13.9 and 11.1 events per 100 child-years in the FD and DE
groups, respectively (FD:DE IRR, 1.26; 95% CI, 0.64–2.49;
).Pp .5
There were no significant differences between randomized
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Figure 2. Time to first primary (A) and secondary (B ) adverse event (AE) outcomes. Primary AEs were grade 3 or 4 AEs with a definite/probable
or uncertain relationship with nevirapine; secondary AEs were grade 2–4 AEs with a definite/probable relationship with nevirapine.
groups for changes in weight-for-age z scores, height-for-age z
scores, and absolute CD4 cell counts or CD4 cell percentages
to 96 weeks ( , , , and , respec-Pp .06 Pp .66 Pp .16 Pp .99
tively). Increases in weight-for-age z scores occurred sooner
and were larger than increases in height-for-age z scores; how-
ever, although increases in weight-for-age z scores slowed be-
tween 48–96 weeks, increases in height-for-age z scores con-
tinued at a similar rate. At 96 weeks, weight-for-age z scores
had increased by a mean of +1.7 and +1.4 in the FD and DE
groups, respectively; height-for-age z scores increased by +0.9
and +0.7, respectively; CD4 cell counts increased by +518 and
+554 cells/mL, respectively; and CD4 cell percentage increased
by +17.3% and +17.3%, respectively. Viral load was !250 cop-
ies/mL in 78% ( ) at 48 weeks and in 75% ( ) atnp 116 np 66
96 weeks, with no differences between groups (74% in FD and
82% in DE at 48 weeks [ ]; 78% in FD and 73% in DEPp .2
at 96 weeks [ ]). Viral load was 11000 copies/mL in 17%Pp .6
( ) and 20% ( ), respectively.np 25 np 18
DISCUSSION
The CHAPAS-1 trial was designed to evaluate dosing strategies
for the pediatric antiretroviral FDCs Triomune Baby and Junior,
which contain different ratios of stavudine, lamivudine, and
nevirapine relative to the adult FDC and result in appropriate
pharmacokinetic parameters in Zambian children [6, 11]. The
US Food and Drug Administration and WHO approved this
pediatric FDC across weight bands down to 3 kg in 2007.
Here, we present a comparison of the safety and longer-term
clinical and immunological outcomes between starting Trio-
mune Baby/Junior at FD versus the recommended 14-day ne-
virapine DE, using a combination of dual- and triple-drug
FDCs. There are few prospective data documenting adverse
reactions to nevirapine in African children, and no random-
ized trials comparing DE and FD strategies in adults or chil-
dren have been conducted. The rationale for the trial was that
nevirapine DE in children requires additional drug formula-
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Table 3. Predictors of Nevirapine Reactions at Antiretroviral Therapy Initiation
Predictor
Nevirapine rash or grade 3 or 4 elevated
ALT or AST level definitely/probably
related to nevirapine Nevirapine rash alone
Univariablea Multivariableb Univariablea Multivariableb
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Female sex 1.63 (0.64–4.16) .31 1.82 (0.61–5.42) .29
Age, per year increase 1.07 (0.96–1.19) .21 1.18 (1.02–1.38) .03 1.14 (1.00–1.29) .05 1.35 (1.10–1.64) .003
CD4 cell count for age, per unit increase 1.08 (0.94–1.25) .28 1.27 (0.98–1.64) .08 1.11 (0.91–1.36) .29 1.51 (1.03–2.20) .03
Weight for age, per unit increase 1.14 (0.84–1.55) .41 1.49 (0.98–2.26) .06 1.50 (0.92–2.45) .11
Height for age, per unit increase 1.00 (0.73–1.38) .99 1.39 (0.87–2.20) .16
Elevated hemoglobin level, per unit increase 1.12 (0.82–1.54) .47 1.40 (0.95–2.05) .09
Elevated ALT level, per unit increase 1.00 (0.98–1.02) .97 1.00 (0.98–1.02) .94
Elevated AST level, per unit increase 1.00 (0.99–1.01) .70 1.00 (0.98–1.01) .70
FD (vs DE) 7.16 (1.97–26.0) .003 9.79 (1.97–48.6) .005
NOTE. Nonlinear associations with continuous variables were investigated using fractional polynomials, but none were found (ie, there was no evidence of
any threshold at which risk increased or decreased more quickly). ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; DE,
dose escalation; FD, full dose; OR, odds ratio.
a Univariable results were also adjusted for FD vs DE (data not shown).
b Multivariable models were based on backward selection using Akaike’s information criterion.
tions that for syrups are difficult to procure and complex to
administer: the dual pediatric lamivudine-stavudine FDC was
not available when the trial commenced. Guidelines mandat-
ing nevirapine DE may therefore be a significant barrier to ART
initiation in children. In addition, early adverse reactions to
nevirapine have been reported to be less frequent among chil-
dren [7, 8] than adults [13, 14], suggesting that DE might be
less important in children. Thus, if starting with FD Triomune
Baby or Junior resulted in few additional AEs, there could be
substantial benefits to program planners from not having to
procure extra formulations for nevirapine DE.
The CHAPAS-1 DE strategy was once-daily Triomune Baby
or Junior in the morning given with once-daily Lamivir-S Baby
or Junior in the evening (lamivudine-stavudine in the same
doses as Triomune Baby and Junior), manufactured for the trial
by Cipla as scored dispersible tablets. This DE strategy is con-
siderably less costly than separate syrups for each drug in the
FDC and is simpler for caregivers and dispensing providers, as
well as procurers. One alternative strategy considered was to
give a half dose of the whole FDC (ie, half-dose lamivudine-
stavudine as well as half-dose nevirapine) for the first 2 weeks.
However, the risk of early resistance development from initial
lamivudine underdosing was considered greater than the risk
of nevirapine toxicity from starting a FD FDC, especially in
young children [15]. We found the dual or triple FDC DE
approach was very acceptable; the color and shape of the tablets
are distinct, and at the 2 week visit nurse questionnaires iden-
tified very few wrong doses (data not shown). In addition, at
trial exit carers and older children reported by questionnaire
that it was easy to initiate ART using these drug formulations.
The CHAPAS-1 primary end point was grade 3 or 4 clinical
or laboratory AEs (according to reference toxicity tables) with
a definite/probable or uncertain relationship to nevirapine.
Similar proportions of children had primary end points in each
randomized group, but clinical relevance is limited as most
were single grade 3 elevations in liver enzyme or bilirubin levels,
which were asymptomatic and resolved spontaneously without
stopping nevirapine or changing the dose. The elevated liver
enzyme levels generally occurred soon after ART initiation, and
there was little overlap with nevirapine-associated rash. Our
results add to those of the DART trial, which showed no dif-
ference in ART-modifying AEs among African adults receiving
routine versus clinically driven biochemistry monitoring, in-
cluding among those receiving nevirapine [16, 17]. The results
of both trials suggest that routine liver function tests are not
required after nevirapine initiation in resource-limited settings.
The grade 3 elevations in bilirubin levels are unexplained and
occurred throughout the trial, if anything more frequently in
the DE group; although investigated, laboratory error cannot
be excluded.
However, we did observe significantly more grade 1 or 2
rashes in the FD group. Management varied, but most children
temporarily interrupted nevirapine and subsequently restarted
successfully with DE. Only 3 substituted efavirenz: 1 in the FD
group early during the trial, 1 in the DE group, and the only
child in the FD group who experienced a recurrent rash on
rechallenge with nevirapine DE. Of note, only 1 child was
“treated through” the rash, and it is possible that more could
have been managed with this approach. Only 2 children with
rashes were admitted to the hospital: 1 early during the trial,
and the child who was treated though; however, both were
admitted for observation, not because of rash severity. Clini-
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cians were not masked to randomized group, which introduces
the possibility of ascertainment bias; however, a small, nonsig-
nificant increase in nevirapine concentration was observed in
children who developed rash (data not shown). We are con-
fident that we did not miss any serious reactions among chil-
dren early during the trial, when mortality was high; further-
more, only 1 child died during the first month of ART in the
FD group, compared with 4 deaths in the DE group.
A nonsignificantly higher risk of nevirapine rash was ob-
served among females, as has been reported in adults [18].
Older children and those with higher CD4 cell counts were
also more likely to develop nevirapine rash, in keeping with
the more immature immune systems of younger children and
with results observed among adults [19, 20]. Although we ob-
served different rates of grade 1 or 2 rashes in the CHAPAS-1
DE and FD groups, our findings broadly agree with previous
results showing lower clinical event rates among children than
adults [7, 8, 13, 14, 21]. Hepatotoxicity has also been reported
more frequently among adults than children in previous studies
[7, 8, 20]; in CHAPAS-1, although rates of single elevated liver
enzyme levels differed between randomized groups, no child
had confirmed (second) elevated levels of liver enzymes.
DE using Lamivir-S does not increase drug costs, compared
with FD initiation using Triomune Baby and Junior. However,
with DE using syrups the cost of preventing 1 grade 1 or 2
rash is approximately $40. An alternative way to escalate the
dose (not evaluated in this trial) is to use cut parts of unscored
adult lamivudine-stavudine tablets for the first 2 weeks of ART,
when inaccuracies dividing tablets may be less important.
In CHAPAS-1, more than half the deaths occurred during
the first 3 months of ART, most commonly due to diarrhoea
and pneumonia. Similar findings have been reported in pedi-
atric cohorts in resource-limited settings [22, 23], including
Zambia [24]. There were no differences between randomized
groups in any measure of HIV disease, including weight or
height gains, CD4 cell percentage, and viral load response to
ART. As reported elsewhere, CD4 cell response is good in chil-
dren, and HIV RNA suppression at 48 weeks was comparable
to data from previously untreated children in well-resourced
[25, 26] and resource-limited [27] countries. These data boost
our confidence that triple FDC generic “minipills” for children
are appropriate for African children.
In conclusion, we have shown that rash occurred more fre-
quently among children starting nevirapine at FD, although
88% had no clinical toxicity. Elevated AST or ALT values were
unconfirmed, transient, and resolved spontaneously, suggest-
ing that routine laboratory monitoring has limited value. Wher-
ever possible, dual pediatric stavudine-lamivudine minitablets
should be made available for safe and simple DE, which is more
cost-effective than syrups. If dual-drug adult or pediatric solid
formulations are not available and FD Triomune Baby or Junior
tablets are used, caregivers should be aware of the timing of
rash. For children developing rash, the options are to treat
through with careful clinical observation or to reduce to half-
dose Triomune during reescalation, given that we observed few
recurrences of rash with DE after rash following initiation with
FD nevirapine.
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